919.865.1117
tallen@wyrick.com
Bio
Tom practices in the areas of venture capital, private equity, corporate finance, mergers and acquisitions, and general company representation. He advises venture capital and private equity funds in their formation and investment activities. He counsels entrepreneurs and companies in a wide range of matters, including formation and corporate governance, securities offerings and fundraising, mergers and acquisitions, employee incentive programs, and strategic relationships. Prior to joining the firm, Tom was a corporate associate at Latham & Watkins LLP. Tom received his B.A., cum laude, from Harvard University and his J.D., cum laude, from Harvard Law School.
- Listed as “Raleigh Best Lawyers Venture Capital Lawyer of the Year” (2024)
- Listed among The Best Lawyers in America: Venture Capital Law (2018-2024), Biotechnology and Life Sciences Practice (2019-2024), Corporate Law (2021-2024), Mergers and Acquisitions Law (2021-2024)
- Listed among Business North Carolina Magazine Legal Elite: Business (2022)
- North Carolina State Bar
- American Bar Association
- Served as company counsel for $2 million Series Seed Preferred Stock financing of a digital security company
- Served as investor counsel for $10 million Series C Preferred Stock financing of digital healthcare company
- Served as fund counsel for the formation of a private equity fund with a target size of $100 million
- Served as investor counsel for $3 million Series A Preferred Stock financing of a fintech company
- Served as company counsel for $20 million Series A Preferred Stock financing of a life sciences company
- Served as fund counsel for the formation of a venture capital fund with a target size of $200 million
- Served as investor counsel for $5 million Series B Preferred Stock financing of a pharmaceutical company
- Served as investor counsel for $1 million Series Seed Preferred Stock financing of a digital healthcare company
- Served as company counsel for $6 million Convertible Promissory Note and Warrant financing of a biotechnology company
- Served as fund counsel for the formation of a special purpose investment vehicle with $30 million in committed capital
